- Home
- CTRE vs GH Comparison
CTRE vs GH Comparison
Compare CTRE & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRE
- GH
- Stock Information
- Founded
- CTRE 2013
- GH 2011
- Country
- CTRE United States
- GH United States
- Employees
- CTRE N/A
- GH N/A
- Industry
- CTRE Real Estate Investment Trusts
- GH Medical Specialities
- Sector
- CTRE Real Estate
- GH Health Care
- Exchange
- CTRE Nasdaq
- GH Nasdaq
- Market Cap
- CTRE 5.7B
- GH 4.9B
- IPO Year
- CTRE N/A
- GH 2018
- Fundamental
- Price
- CTRE $28.74
- GH $40.62
- Analyst Decision
- CTRE Buy
- GH Strong Buy
- Analyst Count
- CTRE 7
- GH 21
- Target Price
- CTRE $30.86
- GH $52.81
- AVG Volume (30 Days)
- CTRE 1.5M
- GH 2.3M
- Earning Date
- CTRE 05-01-2025
- GH 04-30-2025
- Dividend Yield
- CTRE 4.66%
- GH N/A
- EPS Growth
- CTRE 73.08
- GH N/A
- EPS
- CTRE 0.95
- GH N/A
- Revenue
- CTRE $329,837,000.00
- GH $773,996,000.00
- Revenue This Year
- CTRE $16.31
- GH $23.05
- Revenue Next Year
- CTRE $21.22
- GH $21.40
- P/E Ratio
- CTRE $30.25
- GH N/A
- Revenue Growth
- CTRE 43.26
- GH 28.20
- 52 Week Low
- CTRE $24.35
- GH $20.14
- 52 Week High
- CTRE $33.15
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- CTRE 50.51
- GH 48.45
- Support Level
- CTRE $28.26
- GH $37.73
- Resistance Level
- CTRE $29.36
- GH $39.63
- Average True Range (ATR)
- CTRE 0.62
- GH 1.60
- MACD
- CTRE -0.06
- GH -0.01
- Stochastic Oscillator
- CTRE 49.88
- GH 60.00
About CTRE CareTrust REIT Inc.
CareTrust REIT Inc is a self-administered, publicly-traded REIT engaged in the ownership, acquisition, financing, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. The company has one reportable segment consisting of investments in healthcare-related real estate assets. It generates revenues by leasing healthcare-related properties to healthcare operators in triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.